Parasite
Antiparasitics are a class of medications which are indicated for the treatment of parasitic diseases such as nematodes, cestodes, trematodes, and infectious protozoa.
Parasite Isoform Specific Products
All Product Categories
-
Parasite Related Products (2569)
Related Products (2569)
-
Related Compound Screening Libraries (1)
-
Parasite Isoform Comparison
-
Antileishmanial agent-19
0 ImagesAntileishmanial agent-19 (Compound F27) is an antileishmanial agent, with a IC50 of 3.39 μM for L. donovani promastigotes. Antileishmanial agent-19 inhibits Leishmania prolyl-tRNA synthetase. Antileishmanial agent-19 inhibits host PI3K/Akt/CREB axis-mediated IL-10 secretion. Antileishmanial agent-19 induces autophagy-mediated apoptosis in L. donovani promastigotes. Antileishmanial agent-19 reduces parasite burden in L.d-infected animals.
-
Fenbendazole sulfone
0 ImagesSynonyms: Oxfendazole sulfone; FBZ-SO2Fenbendazole sulfone (Oxfendazole sulfone) is a metabolite of Fenbendazole (HY-B0413) and benzimidazole Anthelmintic. Fenbendazole sulfone occurs in cow's milk. Fenbendazole sulfone serves as a marker residue component in cow's milk.
-
Gypsogenic acid
0 ImagesGypsogenic acid is a triterpenoid acid that can be isolated from Miconia stenostachya and has antibacterial and trypanoidal activities. The MICs values of Gypsogenic acid for the oral bacterial pathogens Enterococcus faecalis, Streptococcus salivarius, Streptococcus haematococcus, Streptococcus mutans and sobrinus were 50-200 μg/mL. Gypsogenic acid can induce blood cortensite cleavage in isolated mice with IC50 56.6 μM.
-
Fenbendazole analog-1
0 ImagesFenbendazole analog-1 (compound 9) is a 2-methoxycarbonylamino-derived antiparasitic compound and inhibits rat brain tubulin polymerization. Fenbendazole analog-1 inhibits the growth of the protozoa Giardia lamblia, Entamoeba histolytica, and the worm Trichinella spiralis.
-
Mebendazole (Standard)
0 ImagesMebendazole (Standard) is the analytical standard of Mebendazole. This product is intended for research and analytical applications. Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration.
-
Robenidine
0 ImagesRobenidine is a coccidiostat agent that can be used for the research of coccidiosis caused by parasites in the Eimeria genus.
-
AWZ1066S
0 ImagesAWZ1066S is a highly potent, specific and orally active anti-Wolbachia agent with EC50 value of 121 nM. AWZ1066S also is a weak CYP2C9 inhibitor and a weak CYP3A4 inducer with IC50 values of 9.7 μM and 37 uM, respectively. AWZ1066S can be used for the research of tropical diseases such as Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) .
-
RYL-552S
0 ImagesRYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro.
-
Cabamiquine succinate
0 ImagesSynonyms: DDD107498 succinate; DDD-498 succinate; M5717 succinateCabamiquine (DDD107498) succinate is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. Cabamiquine succinate inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2.
-
SARS-CoV-IN-3
0 ImagesSARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells.
-
UCT943
0 ImagesUCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC50 of 23 nM.
-
SARS-CoV-IN-1
0 ImagesSARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities.
-
SARS-CoV-IN-2
0 ImagesSARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities.
-
Cethromycin-d6
0 ImagesCat. No.: HY-19655SSynonyms: ABT-773-d6; Abbott-195773-d6; A-195773-d6Cethromycin-d6 (ABT-773-d6; Abbott-195773-d6; A-195773-d6) is the d6-labeled Cethromycin (HY-19655). Cethromycin (ABT-773; Abbott-195773) is an orally effective ketolide antibiotic with broad-spectrum antibacterial activity. Cethromycin binds to domains II/V of the 23S rRNA of the 50S subunit, inhibiting bacterial protein synthesis. Cethromycin can accumulate in lung tissue, alveolar macrophages, epithelial lining fluid, and human polymorphonuclear leukocytes. Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Mycoplasma pneumoniae. Cethromycin exhibits significant intracellular and pulmonary enrichment and anti-inflammatory effects against mycoplasma pneumonia in mouse models, improving airway obstruction and airway hyperresponsiveness. Cethromycin disrupts the apicoplast and reduces liver-stage parasite burden during the liver stage of Plasmodium berghei. Cethromycin can be used in research related to pneumonia, Staphylococcus aureus infection, gonorrhea, and malaria.
-
Anti-Mouse CD209b Antibody (22D1)
0 ImagesCat. No.: HY-P99122Purity: 99.00%Anti-Mouse CD209b Antibody (22D1) is an anti-mouse CD209b IgG1 antibody inhibitor derived from the host Armenian Hamster. Anti-Mouse CD209b Antibody (22D1) can block SIGN-R1. Anti-Mouse CD209b Antibody (22D1) can be used for the researches of infection, inflammation and immunology, such as toxoplasma infection and pneumonia.
-
DSM502
0 ImagesDSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs.
-
GSK3494245
0 ImagesSynonyms: DDD01305143GSK3494245 (DDD01305143) is a potent, orally active, and selective inhibitor of the chymotrypsin-like activity of the parasite proteasome binding in a site sandwiched between the β4 and β5 subunits (IC50=0.16 μM for WT L. donovani proteasomes). GSK3494245 moderately inhibits chymotrypsin-like activity of human proteasome (IC50: purified 26S=13 µM; enriched THP-1 extracts IC50=40µM). GSK3494245 exhibits attractive biological and biosafety properties.
-
Amodiaquine-d10
0 ImagesCat. No.: HY-B1322ASCAS No.: 1189449-70-4Amodiaquine-d10 is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect.
-
Hydroxychloroquine-d4-1 sulfate
0 ImagesCat. No.: HY-W031727SCAS No.: 1216432-56-2Hydroxychloroquine-d4-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
-
Clindamycin-d3 hydrochloride
0 ImagesCat. No.: HY-B1455SCAS No.: 1356933-72-6Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
